The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro

Krivenko L.V.; Sviridova A.A.; Melnikov M.V.; Rogovskii V.S.; Boyko A.N.; Pashenkov M.V.

doi:https://doi.org/10.17116/jnevro202012007267

Krivenko L.V.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

Scopus AuthorID: 57218656234
ORCID: 0000-0002-2314-8652

Sviridova A.A.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

SPIN RSCI: 6291-3236
Scopus AuthorID: 57209272018
ORCID: 0000-0003-1086-9052

Melnikov M.V.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of FMBA;
Institute of Immunology of FMBA

SPIN RSCI: 6636-6419
Scopus AuthorID: 57221797118
ORCID: 0000-0001-6880-3668

Rogovskii V.S.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency;
Pirogov Russian National Research Medical University

ORCID: 0000-0002-3682-6571

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Pashenkov M.V.

National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia

SPIN RSCI: 8690-0830
Scopus AuthorID: 56616259500
ORCID: 0000-0002-6995-1790

The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro

Authors:

Krivenko L.V., Sviridova A.A., Melnikov M.V., Rogovskii V.S., Boyko A.N., Pashenkov M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2): 67‑72

DOI: 10.17116/jnevro202012007267

Read: 2069 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Krivenko LV, Sviridova AA, Melnikov MV, Rogovskii VS, Boyko AN, Pashenkov MV. The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2):67‑72. (In Russ.)
https://doi.org/10.17116/jnevro202012007267

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

THE AIM OF THE STUDY

Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS).

MATERIAL AND METHODS

5 patients with relapsing-remitting MS and five healthy subjects were examined. Levels of IL-6 and IL-1β were measured by ELISA in culture supernatants obtained from lipopolysaccharide stimulated dendritic cells. To assess the effect of fluoxetine on cytokine production, dendritic cells were stimulated in the presence of fluoxetine and antagonists of 5-HT_1A-, 5-HT_2A-, 5-HT_2B-receptors or agonist of 5-HT_2B-receptors.

RESULTS

Cytokine production by dendritic cells was comparable in both groups. Fluoxetine suppressed IL-6 and IL-1β production in both groups. Blockade of 5-HT_2B-receptors with specific antagonist RS 127445 reduced the inhibitory effect of fluoxetine on IL-1β production in both groups and IL-6 production in healthy subjects. In contrast, activation of 5-HT_2B-receptors by specific agonist BW 723C86 increased the inhibitory effect of fluoxetine on IL-6 production by dendritic cells in both groups, but did not affect on IL-1β production.

CONCLUSION

These data suggest an anti-inflammatory effect of fluoxetine in MS by modulating pro-inflammatory cytokines production by dendritic cells. This effect could be mediate by activation of 5-HT_2B-receptors.

Keywords:

fluoxetine

5-HT2B-receptors

dendritic cells

interleukin-6

interleukin-1β

multiple sclerosis

Authors:

Krivenko L.V.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

Scopus AuthorID: 57218656234
ORCID: 0000-0002-2314-8652

Sviridova A.A.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

SPIN RSCI: 6291-3236
Scopus AuthorID: 57209272018
ORCID: 0000-0003-1086-9052

Melnikov M.V.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of FMBA;
Institute of Immunology of FMBA

SPIN RSCI: 6636-6419
Scopus AuthorID: 57221797118
ORCID: 0000-0001-6880-3668

Rogovskii V.S.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency;
Pirogov Russian National Research Medical University

ORCID: 0000-0002-3682-6571

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Pashenkov M.V.

National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia

SPIN RSCI: 8690-0830
Scopus AuthorID: 56616259500
ORCID: 0000-0002-6995-1790

Received:

14.05.2020

Accepted:

18.05.2020

Close metadata

References:

Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406-419. https://doi.org/10.1016/S1474-4422(14)70305-9
Melnikov MV, Pashenkov MV, Boyko AN. Dendritic cells in multiple sclerosis. Journal of Neurology and Psychiatry. S.S. Korsakov. 2017;117(2):22-30. (In Russ.).
Sie C, Korn T. Dendritic cells in central nervous system autoimmunity. Semin Immunopathol. 2017;39(2):99-111. https://doi.org/10.1007/s00281-016-0608-7
Melnikov M, Rogovskii V, Boyko A, Pashenkov M. The influence of biogenic amines on Th17-mediated immune response in multiple sclerosis. Mult Scler Relat Disord. 2018;12:21:19-23. https://doi.org/10.1016/j.msard.2018.02.012
Boyko A, Melnikov M, Ghetishev R, Pashenkov M. The role of biogenic amines in regulation of interaction between immune and nervous systems in multiple sclerosis. Neuroimmunomodulation. 2016;23(4):217-223. https://doi.org/10.1159/000449167
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. https://doi.org/10.1212/wnl.33.11.1444
Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109-1118.
Han TH, Jin P, Ren J, Slezak S, Marincola FM, Stroncek DF. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother. 2009;32(4):399-407. https://doi.org/10.1097/CJI.0b013e31819e1773
Branco-de-Almeida LS, Kajiya M, Cardoso CR, Silva MJ, Ohta K, Rosalen PL, Franco GC, Han X, Taubman MA, Kawai T. Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes. FEMS Immunol Med Microbiol. 2011;62(3):283-294. https://doi.org/10.1111/j.1574-695X.2011.00816.x
Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain. 2001;124(Pt 3):480-492.
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337-341. https://doi.org/10.1038/nature14432
De Laere M, Berneman ZN. Cools N. To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. J Neuropathol Exp Neurol. 2018;77(3):178-192. https://doi.org/10.1093/jnen/nlx114
Prado C, Gaiazzi M, González H, Ugalde V, Figueroa A, Osorio-Barrios FJ, López E, Lladser A, Rasini E, Marino F, Zaffaroni M, Cosentino M, Pacheco R. Dopaminergic Stimulation of Myeloid Antigen-Presenting Cells Attenuates Signal Transducer and Activator of Transcription 3-Activation Favouring the Development of Experimental Autoimmune Encephalomyelitis. Front Immunol. 2018;9:571. https://doi.org/10.3389/fimmu.2018.00571
Takenaka MC, Araujo LP, Maricato JT, Nascimento VM, Guereschi MG, Rezende RM, Quintana FJ, Basso AS. Norepinephrine Controls Effector T Cell Differentiation through β2-Adrenergic Receptor-Mediated Inhibition of NF-κB and AP-1 in Dendritic Cells. J Immunol. 2016;196(2):637-644. https://doi.org/10.4049/jimmunol.1501206
Müller T, Dürk Th, Blumenthal B, Grimm M, Cicko S, Panther E, Sorichter St, Herouy Y, Di Virgilio Fr, Ferrari D, Norgauer J, Idzko M. 5-Hydroxytryptamine Modulates Migration, Cytokine and Chemokine Release and T-Cell Priming Capacity of Dendritic Cells In Vitro and In Vivo. PLoS One. 2009;4(7):e6453. https://doi.org/10.1371/journal.pone.0006453
Sviridova AA, Melnikov MV, Belousova OO, Rogovskii VS, Pashenkov MV, Boyko AN. Serotonergic system as a therapeutic target in multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119:2(2):64-72. (In Russ.). https://doi.org/10.17116/jnevro20191192264
Bhat R, Mahapatra S, Axtell RC, Steinman L. Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. J Neuroimmunol. 2017;313:77-81. https://doi.org/10.1016/j.jneuroim.2017.10.012
Mitsonis CI, Zervas IM, Potagas CM, Mitropoulos PA, Dimopoulos NP, Sfagos CA, Papadimitriou GN, Vassilopoulos DC. Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. Eur Neuropsychopharmacol. 2010;20(2):123-131. https://doi.org/10.1016/j.euroneuro.2009.10.004
Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry. 2008;79(9):1027-1031. https://doi.org/10.1136/jnnp.2007.139345
Idzko M, Panther E, Stratz C. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol. 2004;172:6011-6019.
Szabo A, Gogolak P, Koncz G, Foldvari Z, Pazmandi K, Miltner N, Poliska S, Bacsi A, Djurovic S, Rajnavolgyi E. Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells. Sci Rep. 2018;8(1):1765. https://doi.org/10.1038/s41598-018-20173-y
Katoh N, Soga F, Nara T, Tamagawa-Mineoka R, Nin M, Kotani H, Masuda K, Kishimoto S. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin Exp Immunol. 2006;146(2):354-361.